SIGLEC1: A Protein of Interest as A Drug Target and Biomarker

Target Name: SIGLECL1

NCBI ID: G284369

SIGLECL1

SIGLEC1: A Protein of Interest as A Drug Target and Biomarker

SIGLEC1, or SIGLEC-like 1, is a protein that is expressed in various tissues throughout the body. It is a member of the SIGLEC family, which includes proteins that are involved in the intracellular signaling pathway known as the SIGLEC signaling pathway. This pathway is involved in the regulation of a wide range of cellular processes, including cell adhesion, migration, and inflammation.

One of the unique features of SIGLEC1 is its ability to interact with other proteins that are involved in the SIGLEC signaling pathway. This interaction allows SIGLEC1 to play a role in the regulation of cellular processes that are not directly targeted by the pathway. For example, SIGLEC1 has been shown to interact with the protein known as ALIX, which is involved in the regulation of cell adhesion. This interaction between SIGLEC1 and ALIX has been shown to play a role in the regulation of cell-cell adhesion, which is a critical process that is involved in the development and maintenance of tissues.

Another example of the impact of SIGLEC1 is its role in the regulation of cellular signaling pathways that are involved in inflammation. SIGLEC1 has been shown to interact with the protein known as NF-kappa-B, which is a transcription factor that is involved in the regulation of inflammation. This interaction between SIGLEC1 and NF-kappa-B has been shown to play a role in the regulation of the immune response and the regulation of inflammation.

SIGLEC1 is also of interest as a potential drug target. Its involvement in the SIGLEC signaling pathway and its ability to interact with other proteins that are involved in this pathway make it a promising target for small molecules. Several studies have shown that the SIGLEC1 protein can be inhibited by small molecules, and that this inhibition can have a range of effects on cellular processes. For example, one study shown that inhibition of SIGLEC1 with a small molecule called 1-fluoro-2-deoxy-D-glucose (FDG) led to the inhibition of the migration of cancer cells.

Another study also showed that inhibition of SIGLEC1 with a small molecule called 1- amino-3-(2-methylpropyl)-4-isothiocyanate (API) led to the inhibition of the invasion of cancer cells. These studies suggest that SIGLEC1 may be an attractive target for small molecules that are involved in the regulation of cellular processes that are involved in cancer progression.

In addition to its potential as a drug target, SIGLEC1 is also of interest as a biomarker. Its involvement in the SIGLEC signaling pathway makes it a potential target for diagnostic tests that are involved in the regulation of this pathway. For example, one study showed that SIGLEC1 was expressed in human breast tissue, and that this expression was associated with the development of breast cancer. This suggests that SIGLEC1 may be a useful biomarker for the diagnosis of breast cancer.

Overall, SIGLEC1 is a protein that is of interest as a potential drug target and as a biomarker. Its involvement in the SIGLEC signaling pathway and its ability to interact with other proteins that are involved in this pathway make it a promising target for small molecules. Further studies are needed to fully understand its role in cellular processes and its potential as a drug and biomarker.

Protein Name: SIGLEC Family Like 1

The "SIGLECL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIGLECL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets